Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBT (2016 - 2025)

Historic EBT for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$62.0 million.

  • Regenxbio's EBT fell 392.14% to -$62.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$178.1 million, marking a year-over-year increase of 2551.16%. This contributed to the annual value of -$227.1 million for FY2024, which is 1386.1% up from last year.
  • Per Regenxbio's latest filing, its EBT stood at -$62.0 million for Q3 2025, which was down 392.14% from -$70.9 million recorded in Q2 2025.
  • Regenxbio's 5-year EBT high stood at $307.5 million for Q4 2021, and its period low was -$76.8 million during Q1 2022.
  • In the last 5 years, Regenxbio's EBT had a median value of -$61.9 million in 2023 and averaged -$39.8 million.
  • The largest annual percentage gain for Regenxbio's EBT in the last 5 years was 85925.23% (2021), contrasted with its biggest fall of 76459.95% (2021).
  • Quarter analysis of 5 years shows Regenxbio's EBT stood at $307.5 million in 2021, then crashed by 119.51% to -$60.0 million in 2022, then fell by 5.11% to -$63.0 million in 2023, then rose by 18.67% to -$51.3 million in 2024, then decreased by 20.85% to -$62.0 million in 2025.
  • Its EBT stands at -$62.0 million for Q3 2025, versus -$70.9 million for Q2 2025 and $6.1 million for Q1 2025.